WO2009027786A3 - Matrix dosage forms of varenicline - Google Patents

Matrix dosage forms of varenicline Download PDF

Info

Publication number
WO2009027786A3
WO2009027786A3 PCT/IB2008/002165 IB2008002165W WO2009027786A3 WO 2009027786 A3 WO2009027786 A3 WO 2009027786A3 IB 2008002165 W IB2008002165 W IB 2008002165W WO 2009027786 A3 WO2009027786 A3 WO 2009027786A3
Authority
WO
WIPO (PCT)
Prior art keywords
varenicline
matrix dosage
dosage forms
insoluble
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2008/002165
Other languages
French (fr)
Other versions
WO2009027786A2 (en
Inventor
Michael B Fergione
Barbara A Johnson
Ernest S Quan
Neha B Vatsaraj
Original Assignee
Pfizer
Michael B Fergione
Barbara A Johnson
Ernest S Quan
Neha B Vatsaraj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Michael B Fergione, Barbara A Johnson, Ernest S Quan, Neha B Vatsaraj filed Critical Pfizer
Publication of WO2009027786A2 publication Critical patent/WO2009027786A2/en
Publication of WO2009027786A3 publication Critical patent/WO2009027786A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The present invention provides matrix dosage form comprising varenicline or a pharmaceutically acceptable salt thereof, at least one high molecular weight water soluble polymer; and at least one water-insoluble, hydrophilic excipient.
PCT/IB2008/002165 2007-08-29 2008-08-18 Matrix dosage forms of varenicline WO2009027786A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96865507P 2007-08-29 2007-08-29
US60/968,655 2007-08-29

Publications (2)

Publication Number Publication Date
WO2009027786A2 WO2009027786A2 (en) 2009-03-05
WO2009027786A3 true WO2009027786A3 (en) 2009-05-07

Family

ID=40263545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002165 WO2009027786A2 (en) 2007-08-29 2008-08-18 Matrix dosage forms of varenicline

Country Status (1)

Country Link
WO (1) WO2009027786A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432022B (en) * 2018-12-10 2021-07-06 江苏豪森药业集团有限公司 Pharmaceutical composition containing valnemadex tartrate and preparation method thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180058644A (en) * 2016-11-24 2018-06-01 에스케이케미칼 주식회사 Sustained release pharmaceutical formulation of varenicline and preparation method thereof
KR102463733B1 (en) * 2017-06-30 2022-11-04 한미약품 주식회사 Pharmaceutical composition comprising Varenicline Oxalate with improved content uniformity and stability
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
US11602537B2 (en) * 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045437A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
US20060084656A1 (en) * 2004-10-15 2006-04-20 Pfizer Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045437A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
US20060084656A1 (en) * 2004-10-15 2006-04-20 Pfizer Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432022B (en) * 2018-12-10 2021-07-06 江苏豪森药业集团有限公司 Pharmaceutical composition containing valnemadex tartrate and preparation method thereof

Also Published As

Publication number Publication date
WO2009027786A2 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2010035273A3 (en) Novel gastroretentive delivery system
WO2013158814A8 (en) Immediate release, abuse deterrent pharmaceutical compositions
WO2007050294A3 (en) Liquid dosage forms having enteric properties of delayed and then sustained release
WO2009144550A3 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
WO2006073950A3 (en) Nanoparticles for protein drug delivery
WO2008037716A3 (en) Pharmaceutical compositions comprising nilotinib or its salt
HK1118011A1 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation, and their use in the pharmaceutical field
WO2006132647A3 (en) Antimicrobial copolymers and uses thereof
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO2011062965A8 (en) Targeting monomers and polymers having targeting blocks
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2007135193A3 (en) Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
WO2008064202A3 (en) Modified-release formulations of calcium receptor-active compounds
WO2009010842A3 (en) Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2010021607A3 (en) Pharmaceutical formulation
WO2007144169A3 (en) Entacapone-derivatives
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
WO2008021410A3 (en) Highly pure pemetrexed diacid and processes for the preparation thereof
EP2153834A3 (en) Extended release pharmaceutical compositions comprising quetiapine salts
WO2009027786A3 (en) Matrix dosage forms of varenicline
ZA200808465B (en) Pharmaceutical formulations:salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
WO2009134079A3 (en) Pharmaceutical formulation
EP2241310A3 (en) Modified release formulations of emoxypine
WO2009068708A8 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2009001099A3 (en) A pharmaceutical composition comprising polyaphron dispersion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08789106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08789106

Country of ref document: EP

Kind code of ref document: A2